Both SLC7A11 and GPX4 were found to be downregulated in the hyperoside group (Fig. 2D-E), and hyperoside was confirmed to significantly lower SLC7A11 and GPX4 mRNA (Fig. 2F-G) and protein (Fig. 2H-J) levels within treated CML cells. This evidence concerns the gene SLC7A11 and chronic myelogenous leukemia, BCR-ABL1 positive.